CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

Sapio Sciences Announces Enhanced Capabilities for Chemistry, Immunogenicity, GMP and Molecular Biology

Sapio Sciences’ Release 24.12 enhances lab informatics with improved GMP workflows and molecular biology features, driving efficiency and scientific discovery.

January 14, 2025

Alfasigma’s PBC treatment Ocaliva to face an FDA adcomm in September

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 10, 2024

Stakeholders weigh in on potential reforms to FDA advisory committee process

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.